Ideagen PLC Exercise of Options and Total Voting Rights (0231B)
18 September 2018 - 1:42AM
UK Regulatory
TIDMIDEA
RNS Number : 0231B
Ideagen PLC
17 September 2018
Ideagen PLC
("Ideagen," "the Company" or the "Group")
Exercise of Options, issue of shares and Total Voting Rights
Ideagen PLC (AIM: IDEA), a leading supplier of Information
Management Software to highly regulated industries, announces that
it has allotted a total of 65,000 new ordinary shares of 1 penny
each in the capital of the Company ("Ordinary Shares") following
the exercise of 65,000 options by an employee.
Application has been made to the London Stock Exchange for the
65,000 new Ordinary Shares to be admitted to trading on AIM
("Admission") and it is expected that Admission will become
effective and trading will commence at 8.00 a.m. on 21 September
2018.
After Admission of the 65,000 new Ordinary Shares, and including
the admission of the 14,084,507 new Ordinary Shares that arose from
the conditional placing announced on 13 September 2018, the total
number of Ordinary Shares in issue will be 217,099,518 and the
total number of voting rights will therefore be 217,099,518. This
figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in, the
share capital of the Company under the FCA's Disclosure and
Transparency Rules.
Enquiries:
Ideagen plc 01629 699100
David Hornsby, Executive Chairman
Graeme Spenceley, Finance Director
finnCap Limited 020 7220 0500
Stuart Andrews/Henrik Persson/James Thompson
(Nomad)
Alice Lane (ECM)
About Ideagen plc
Ideagen is a UK-headquartered, global technology company quoted
on the London Stock Exchange AIM market (Ticker: IDEA.L).
The Group provides software and services to organisations
operating within highly regulated industries such as aviation,
banking and finance and life science, with its main operational
premises spread throughout the UK, EU, US, Middle East and SE
Asia.
With an excellent portfolio of software products including
Q-Pulse, Coruson, Pentana Audit, Pentana Performance and
PleaseReview, Ideagen helps its clients reduce costs, improve
operational efficiency, strengthen compliance and oversight and
anticipate and manage every detail of risk.
Currently, more than 3,700 organisations use Ideagen's products
including seven of the top 10 UK accounting firms, all of the top
aerospace and defence companies and 75% of the world's leading
pharmaceutical firms.
Ideagen's diverse and varied customer base includes many
well-known, global brands such as British Airways, Aggreko, BAE,
Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank,
Meggitt, Heineken, Johnson Matthey, Haeco Group and European
Central Bank. As well as this, Ideagen counts 180 hospitals across
the UK and US amongst its client base.
For further information please visit www.ideagen.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFSEAIIDLIT
(END) Dow Jones Newswires
September 17, 2018 11:42 ET (15:42 GMT)
Ideagen (LSE:IDEA)
Historical Stock Chart
From Apr 2024 to May 2024
Ideagen (LSE:IDEA)
Historical Stock Chart
From May 2023 to May 2024